
Only 7% of patients discontinued treatment due to adverse reactions1

Renal Function
Elevations of serum creatinine, usually mild, have been reported. Monitoring of renal function, including measurement of blood urea nitrogen (BUN) or serum creatinine, is recommended prior to the start of AFINITOR therapy and periodically thereafter.
Blood Glucose and Lipids
Hyperglycaemia, hyperlipidaemia and hypertrigylceridaemia have been reported in clinical trials. The majority of cases of hyperglycaemia occurred in patients who had an abnormal fasting glucose level before taking AFINITOR. Monitoring of fasting serum glucose is recommended prior to the start of AFINITOR therapy and periodically thereafter. When possible, optimal glycaemic control should be achieved before starting a patient on AFINITOR.
Hematologic Parameters
Decreased haemoglobin, lymphocytes, neutrophils and platelets have been reported in clinical trials. Monitoring of complete blood count is recommended prior to the start of AFINITOR therapy and periodically thereafter.
Find support resources to download for your patients with advanced renal cell carcinoma here.
Next: Guidelines
**VEGF: vascular endothelial growth factor
Reference:
1. AFINITOR [summary of product information]. Basel Switzerland: Novartis Pharma AG.